ImmuPharma fase III melding
Melding idag 28.11.19 for de av oss som har plukket på lavt nivå :
ImmuPharma and Avion Pharmaceuticals sign exclusive licence and development agreement and trademark agreement for Lupuzor™ with Avion to fund new international Phase III trial and commercialise in the US
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™ in North America (United States). LupuzorTM is ImmuPharma's lead compound, a peptide therapeutic and a first-in class autophagy immunomodulator for systemic lupus erythematosus (SLE or lupus) a potentially life-threatening auto-immune disease. In addition, Lupuzor™ also has the potential for treating other auto-immune diseases other than lupus. A trademark licence agreement also has been signed to allow Avion the use of various trademarks in connection with development, manufacture and commercialisation of products under the Licence and Development Agreement.
https://otp.investis.com/clients/uk/immu_pharma/rns/regulatory-story.aspx?cid=1554&newsid=1347989
Kl 09.10 : åpnet opp 105%
ImmuPharma and Avion Pharmaceuticals sign exclusive licence and development agreement and trademark agreement for Lupuzor™ with Avion to fund new international Phase III trial and commercialise in the US
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™ in North America (United States). LupuzorTM is ImmuPharma's lead compound, a peptide therapeutic and a first-in class autophagy immunomodulator for systemic lupus erythematosus (SLE or lupus) a potentially life-threatening auto-immune disease. In addition, Lupuzor™ also has the potential for treating other auto-immune diseases other than lupus. A trademark licence agreement also has been signed to allow Avion the use of various trademarks in connection with development, manufacture and commercialisation of products under the Licence and Development Agreement.
https://otp.investis.com/clients/uk/immu_pharma/rns/regulatory-story.aspx?cid=1554&newsid=1347989
Kl 09.10 : åpnet opp 105%
Redigert 28.11.2019 kl 09:10
Du må logge inn for å svare
Påskeharen
28.11.2019 kl 10:43
886
Stiger utover dagen ( nå 20,90 GBX = 197% siden åpning på morgenen ) og det lenge før USA åpner.
Husk at denne passerte 190 GBX før den feilet i forrige forsøk på fase III, så potensialet i denne går utenpå det meste.
Husk at denne passerte 190 GBX før den feilet i forrige forsøk på fase III, så potensialet i denne går utenpå det meste.
Redigert 06.12.2019 kl 17:57
Du må logge inn for å svare
Påskeharen
28.11.2019 kl 11:57
864
Nå 28,70 GBX, altså opp 306 % siden åpning på morgenen.
Julen kom tidlig i år !
Julen kom tidlig i år !
Påskeharen
28.11.2019 kl 17:23
829
325 % opp på 1 dag ( 30 GBX ) og dette er faktisk bare begynnelsen.
Ved forrige forsøk på fase III var kursen opp i over 180 GBX så det blir spennende måneder fremover for de som er i denne.
Ved forrige forsøk på fase III var kursen opp i over 180 GBX så det blir spennende måneder fremover for de som er i denne.
Påskeharen
05.12.2019 kl 11:40
685
Påskeharen
06.12.2019 kl 17:43
649
Noe å tygge på i helgen hvis du vurderer en inngang her ( minner om at den gikk helt til ca 190 ved forrige forsøk på fase III )
Nytt pricetarget: 100 !
Strong Buy
Investment bank Life Sciences Division upgraded its share price target to 100p from 76pToday 16:17
ImmuPharma’s Lupuzor could be US blockbuster, says Life Sciences Division
2019-12-06 15:16:00
Investment bank Life Sciences Division upgraded its share price target to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals
ImmuPharma PLC - ImmuPharma s Lupuzor could be US blockbuster, says Life Sciences Division
ImmuPharma PLC’s (LON:IMM) lupus candidate Lupuzor could become a US blockbuster by generating over US$1bn revenues per year, according to Life Sciences Division.
The investment bank raised its target for the AIM-listed drug developer’s share price to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals.
READ: ImmuPharma shoots up 300% after it inks US licensing deal for flagship drug Lupuzor
Avion will fund a new phase III trial, while Immupharma will also receive milestone payments and an agreed 17% royalty on sales.
ImmuPharma has the potential to rack in annual royalties of up to US$170mln from the deal, according to the Life Sciences Division analysts.
This deal is only exclusive to the US market, meaning ImmuPharma can look for other distribution partners in other geographies, such as Europe, where there is no need for a new trial given Avion’s funding commitment.
Further agreements will allow ImmuPharma to multiply income from Lupuzor with other royalties and milestone payments.
According to Life Sciences Division, Lupuzor may get second or third place in the US market if rival AstraZeneca PLC’s (LON:AZN) Anifrolumab gets a US licensing deal.
“Lupuzor with a 71.1% response rate in the anti-ds DNA auto antibody-positive patients, could also eventually be the product with the best overall response rate and safety profile in the market,” LSD analysts added
Nytt pricetarget: 100 !
Strong Buy
Investment bank Life Sciences Division upgraded its share price target to 100p from 76pToday 16:17
ImmuPharma’s Lupuzor could be US blockbuster, says Life Sciences Division
2019-12-06 15:16:00
Investment bank Life Sciences Division upgraded its share price target to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals
ImmuPharma PLC - ImmuPharma s Lupuzor could be US blockbuster, says Life Sciences Division
ImmuPharma PLC’s (LON:IMM) lupus candidate Lupuzor could become a US blockbuster by generating over US$1bn revenues per year, according to Life Sciences Division.
The investment bank raised its target for the AIM-listed drug developer’s share price to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals.
READ: ImmuPharma shoots up 300% after it inks US licensing deal for flagship drug Lupuzor
Avion will fund a new phase III trial, while Immupharma will also receive milestone payments and an agreed 17% royalty on sales.
ImmuPharma has the potential to rack in annual royalties of up to US$170mln from the deal, according to the Life Sciences Division analysts.
This deal is only exclusive to the US market, meaning ImmuPharma can look for other distribution partners in other geographies, such as Europe, where there is no need for a new trial given Avion’s funding commitment.
Further agreements will allow ImmuPharma to multiply income from Lupuzor with other royalties and milestone payments.
According to Life Sciences Division, Lupuzor may get second or third place in the US market if rival AstraZeneca PLC’s (LON:AZN) Anifrolumab gets a US licensing deal.
“Lupuzor with a 71.1% response rate in the anti-ds DNA auto antibody-positive patients, could also eventually be the product with the best overall response rate and safety profile in the market,” LSD analysts added
Redigert 06.12.2019 kl 17:56
Du må logge inn for å svare
Påskeharen
13.12.2019 kl 08:54
571
Melding 13.12.19:
https://www.lse.co.uk/rns/IMM/dual-listing-on-euronext-growth-brussels-xxetks2rk13w6fj.html
Commenting on the dual listing on Euronext Growth, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said:
"This dual listing on Euronext Growth Brussels gives ImmuPharma additional visibility among European investors. Having our shares listed on Europe's largest financial market for biotech companies is in line with the new page in ImmuPharma's future following our recent deal with Avion Pharmaceuticals, who are now funding an international Phase III trial for our lead programme, Lupuzor™. The investment thesis for ImmuPharma and specifically Lupuzor™ has been repositioned and we look forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US. We are confident that our listing on Euronext Brussels will allow us to meet and develop relations with a community of new investors in continental Europe".
Benoît van den Hove, Head of Listing at Euronext Brussels said:
"We are delighted to welcome ImmuPharma on Euronext Growth, and look forward to welcome the Company's management team in Brussels. This secondary listing in Brussels demonstrates the attractiveness of Euronext as a leading venue for biotech and life sciences companies in Europe, even outside our domestic markets. With this operation, ImmuPharma joins the large franchise of 106 Life Science companies (61 Biotech and 45 Medtech companies) currently listed on Euronext's markets, representing a total market capitalisation of €28.5 billion (end of October 2019)".
https://www.lse.co.uk/rns/IMM/dual-listing-on-euronext-growth-brussels-xxetks2rk13w6fj.html
Commenting on the dual listing on Euronext Growth, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said:
"This dual listing on Euronext Growth Brussels gives ImmuPharma additional visibility among European investors. Having our shares listed on Europe's largest financial market for biotech companies is in line with the new page in ImmuPharma's future following our recent deal with Avion Pharmaceuticals, who are now funding an international Phase III trial for our lead programme, Lupuzor™. The investment thesis for ImmuPharma and specifically Lupuzor™ has been repositioned and we look forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US. We are confident that our listing on Euronext Brussels will allow us to meet and develop relations with a community of new investors in continental Europe".
Benoît van den Hove, Head of Listing at Euronext Brussels said:
"We are delighted to welcome ImmuPharma on Euronext Growth, and look forward to welcome the Company's management team in Brussels. This secondary listing in Brussels demonstrates the attractiveness of Euronext as a leading venue for biotech and life sciences companies in Europe, even outside our domestic markets. With this operation, ImmuPharma joins the large franchise of 106 Life Science companies (61 Biotech and 45 Medtech companies) currently listed on Euronext's markets, representing a total market capitalisation of €28.5 billion (end of October 2019)".